|
EP2928915A4
(en)
*
|
2012-12-07 |
2016-07-27 |
Permeon Biolog Inc |
FGF-10 COMPLEX
|
|
EP3610884B1
(en)
|
2013-11-06 |
2021-08-18 |
Merck Sharp & Dohme Corp. |
Peptide containing conjugates for dual molecular delivery of oligonucleotides
|
|
KR102532559B1
(ko)
*
|
2013-12-12 |
2023-05-16 |
라이프 테크놀로지스 코포레이션 |
형질감염을 개선하는 막 투과 펩타이드 및 조성물 그리고 이들을 사용하는 방법
|
|
US10487140B2
(en)
|
2014-01-14 |
2019-11-26 |
Integrated Biotherapeutics, Inc. |
Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
|
|
US10532083B2
(en)
|
2014-02-13 |
2020-01-14 |
Technische Universität München |
Methods for inducing differentiation or conversion of white adipocytes and/or preadipocytes to brown adipocites using FGF8
|
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
EP4183806A3
(en)
|
2014-11-12 |
2023-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
WO2016172187A1
(en)
*
|
2015-04-20 |
2016-10-27 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Methods and compositions related to kras inhibitors
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
US9957325B2
(en)
*
|
2015-10-13 |
2018-05-01 |
Formurex, Inc. |
Synthetic antibody mimic peptides
|
|
CN108463248B
(zh)
|
2015-11-12 |
2022-10-21 |
西雅图基因公司 |
聚糖相互作用化合物及使用方法
|
|
US10604558B2
(en)
*
|
2016-01-05 |
2020-03-31 |
Colorado State University Research Foundation |
Compositions comprising resurfaced cell-penetrating nanobodies and methods of use thereof
|
|
WO2017132235A1
(en)
*
|
2016-01-26 |
2017-08-03 |
Dana-Farber Cancer Institute, Inc. |
METHODS FOR TREATING BRAIN METASTASES USING COMBINATIONS OF ANTI-P13K AND ANTI-mTOR AGENTS
|
|
CN105837665B
(zh)
*
|
2016-05-16 |
2019-04-30 |
江苏大学 |
特异性抑制hb-egf促肿瘤细胞迁移浸润的多肽
|
|
US9611297B1
(en)
|
2016-08-26 |
2017-04-04 |
Thrasos Therapeutics Inc. |
Compositions and methods for the treatment of cast nephropathy and related conditions
|
|
US11524988B2
(en)
|
2016-09-19 |
2022-12-13 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Artificial antigen presenting cells for genetic engineering of immune cells
|
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
AU2017375828B2
(en)
*
|
2016-12-16 |
2021-04-15 |
Avixgen Inc |
Cytoplasmic transduction peptide and intracellular messenger comprising same
|
|
WO2018111051A1
(ko)
*
|
2016-12-16 |
2018-06-21 |
(주)에빅스젠 |
세포막 투과 펩티드 및 이를 포함하는 세포내 전달체
|
|
US12077590B2
(en)
|
2017-02-22 |
2024-09-03 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bispecific antibody for cancer immunotherapy
|
|
WO2018160909A1
(en)
|
2017-03-03 |
2018-09-07 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
KR101933217B1
(ko)
*
|
2017-12-28 |
2018-12-27 |
(주) 에빅스젠 |
피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
|
|
WO2019212752A1
(en)
*
|
2018-05-03 |
2019-11-07 |
University Of Utah Research Foundation |
Oca-b peptide conjugates and methods of treatment
|
|
US20210206857A1
(en)
*
|
2018-05-21 |
2021-07-08 |
Bioprocessia Technologies Llc |
Multivalent protein complexes
|
|
WO2019240430A1
(ko)
*
|
2018-06-14 |
2019-12-19 |
(주) 에빅스젠 |
세포 투과 펩티드와 결합된 융합 단백질 및 융합 단백질 또는 세포 투과 펩티드와 상피세포성장인자를 유효성분으로 포함하는 조성물
|
|
US20210254037A1
(en)
*
|
2018-06-14 |
2021-08-19 |
Avixgen Inc. |
Pharmaceutical composition comprising fusion protein of cell-penetrating peptide and rpe65 for treatment of leber's congenital amaurosis
|
|
GB201815045D0
(en)
|
2018-09-14 |
2018-10-31 |
Univ Ulster |
Bispecific antibody targeting IL-1R1 and NLPR3
|
|
US20230076637A1
(en)
*
|
2020-02-06 |
2023-03-09 |
Ajou University Industry-Academic Cooperation Foundation |
Fusion antibody for presenting antigen-derived t cell antigen epitope or peptide containing same on cell surface, and composition comprising same
|
|
EP4146801B1
(en)
*
|
2020-05-04 |
2025-07-02 |
The Board of Trustees of the Leland Stanford Junior University |
Compositions, systems, and methods for the generation, identification, and characterization of effector domains for activating and silencing gene expression
|
|
JP2023534800A
(ja)
*
|
2020-07-13 |
2023-08-14 |
ナショナル ユニヴァーシティー オブ シンガポール |
ウイルスワクチンおよび腫瘍ワクチンの開発、がん免疫療法、ならびに自己免疫疾患の診断および治療における治療用途のためのペプチド性アジュバント
|
|
WO2023034993A1
(en)
*
|
2021-09-03 |
2023-03-09 |
Gleich Gerald J |
Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases
|
|
CN117736338A
(zh)
*
|
2023-12-08 |
2024-03-22 |
温州医科大学 |
一种角质细胞生长因子-透皮肽融合蛋白及其制备与应用
|
|
EP4711380A1
(en)
*
|
2024-09-16 |
2026-03-18 |
Fundació Institut Hospital del Mar d'Investigacions Mèdiques |
Ligand-dependent corepressor, (lcor), mutants and fragments thereof, and uses for cancer therapy
|